Left ventricular assist device implantation in high risk destination therapy patients: an alternative surgical approach by Louis E Samuels et al.
CASE REPORT Open Access
Left ventricular assist device implantation in high
risk destination therapy patients: an alternative
surgical approach
Louis E Samuels1*, Elena Casanova-Ghosh1, Roberto Rodriguez1 and Christopher Droogan2
Abstract
Left Ventricular Assist Device (LVAD) for Destination Therapy (DT) is an established therapy for end stage heart
failure patients who are not transplant candidates. Many DT patients requiring LVADs have had prior open heart
surgery, the majority of whom had prior sternotomy. In addition, DT patients tend to be older and more likely to
have more significant co-morbidities than their Bridge-To-Transplant (BTT) counterparts. As such, placement of an
implantable LVAD in DT patients can be technically hazardous and potentially prone to more perioperative
complications. The purpose of this report is to describe an alternative implantation approach for the implantation
of the Heartmate II™ LVAD in high risk DT patients.
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Background
Left Ventricular Assist Device (LVAD) for Destination
Therapy (DT) has been an established therapy for over a
decade [1] with the Heartmate VE™ and more recently
with the Heartmate II™ (Thoratec Corporation, Plea-
sonton, CA). The use of this technology for DT has
increased as the number of advanced heart failure
patients continue to grow and the number of available
organs for transplantation has remained essentially
unchanged [2]. As such, more patients are being
screened for DT-LVAD therapy when deemed ineligible
for transplant; a risk strategy tool–the Destination Ther-
apy Risk Score (DTRS)–has been adopted to help deter-
mine operative risk [3,4]. However, certain parameters
are not taken into consideration in the DTRS, including
the presence of prior heart surgery and certain co-mor-
bidities (e.g. COPD, morbid obesity, cerebrovascular and
peripheral vascular disease, intractable arrhythmia, can-
cer, etc.). DTRS values exceeding 16 are considered high
risk; DTRS score exceeding 19 are considered very high
risk. The purpose of this report is to describe an alter-
native implantation technique of the Heartmate II
LVAD for high risk DT patients that minimizes the
potential for surgically related complications.
Cases
Case 1
A 71 year old man with end-stage Idiopathic Dilated
Cardiomyopathy (IDCM) was admitted with acute
decompensated heart failure while on home Inotrope
(Milrinone) therapy. His past medical history (PMH)
was significant for morbid obesity (BMI = 36), hyperten-
sion, hyperlipidemia, diabetes, chronic renal insuffi-
ciency, cerebrovascular disease, and obstructive sleep
apnea. His past surgical history (PSH) consisted of an
ACORN CorCap™ with concomitant mitral valve annu-
loplasty five years earlier and bi-ventricular ICD-pace-
maker. The Destination Therapy Risk Score was
calculated at 20.
Preoperative carotid screening revealed high grade ste-
nosis of both internal carotid arteries. Staged carotid
endarterectomies were performed, after which a HM II
LVAD ™ was implanted. There were no intraoperative
complications. Postoperatively, the patient experienced
respiratory complications with multiple reintubations,
Klebsiella pneumonia, and eventual tracheostomy. In
addition, he also experience atrial and ventricular
arrhythmias requiring multiple adjustments and changes
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in anti-arrhythmic therapies. Two months were required
to wean from the ventilator; the patient was discharged
on postoperative day (POD) 93 and remains alive and
well at home six months since discharge.
Case 2
A 71 year old man with end-stage ischemic cardiomyo-
pathy (ISCM) was admitted with acute decompensated
heart failure accompanied by multiple Implantable Car-
diac Defibrillator (ICD) shocks. His PMH was significant
for chronic renal insufficiency, dyslipidemia, cerebrovas-
cular disease, ventricular arrhythmia, gout, and anemia
of chronic disease. The PSH was significant for coronary
artery bypass grafting (CABG) fourteen years earlier at
which time he suffered a perioperative stroke with sub-
sequent recovery. He also had a single chamber ICD
placed three years earlier. An IABP was placed and
medical management with Milrinone was instituted
prior to the LVAD implant. Significant biochemical and
hematologic abnormalities included a BUN of 65 MG/
DL, Creatinine 2.2 MG/DL, hematocrit (HCT) 30.2%,
PLT count 97 K/UL, and INR 1.5. The Destination
Therapy Risk Score was calculated at 20.
Preoperatively, the patient was treated for upper extre-
mity phlebitis and pneumonia. Two weeks were required
to optimize his condition for the LVAD procedure
including placement of an IABP and Milrinone therapy.
No intraoperative problems were encountered. Post-
operatively, the patient required surgical exploration of
the femoral artery (following IABP removal) including
thrombectomy and vascular repair. In addition, he
required re-intubation from aspiration pneumonia with
subsequent ventilator dependence requiring tracheost-
omy. Six weeks were required to wean from the ventila-
tor during which time he experienced intermittent, but
significant hematuria requiring cystoscopy and fulgura-
tion of bleeding vessels in the prostate and bladder.
Anti-arrhythmic therapy was also adjusted on multiple
occasions to control intermittent ventricular tachycardia.
The patient was discharged on POD# 94 and remains
alive at a rehabilitation facility two months since
discharge.
Case 3
A cachectic 77 year old man end-stage ISCM was
admitted with progressive shortness of breath. His PMH
was significant for an acute anterior wall MI twenty-five
years earlier and multiple percutaneous coronary inter-
ventions over the ensuing years. In addition, he had
multiple ablative procedures for ventricular tachycardia
(VT) and eventual placement of a biventricular ICD.
Over the decades, medical therapy was uptitrated and
optimized until a year prior to admission when hypoten-
sion required reduction in dosing; additionally, he lost
twenty pounds. Socially, he consumes alcohol daily and
smoked 3 packs per day for 35 years, having quit at the
time of his first MI. His height, weight, and BMI on
admission were six feet, 140 pounds, and 1.53 respec-
tively. Intravenous Milrinone therapy was instituted
prior to the LVAD implant. The Destination Therapy
Risk Score was calculated at 17.
The LVAD was implanted with no intraoperative pro-
blems were encountered. Postoperatively, however, the
patient experienced bleeding from the chest tubes requir-
ing bedside re-exploration of the left thoracotomy incision.
A significant amount of blood was found in the left chest
with no identifiable surgical source. Laboratory studies
showed a postoperative INR of 3.1 and a Platelet count of
47 K/UL. Evacuation of the hemothorax and blood pro-
duct transfusion stabilized the situation. The patient devel-
oped hepato-renal failure–maximum total bilirubin19.3
mg/DL and creatinine 4.7 mg/DL– requiring hemodialysis;
these biochemical abnormalities resolved within two
weeks. He did, though, remain intubated and required tra-
cheostomy for ventilator dependence. Pseudomonas bac-
teremia was also diagnosed and treated with quinolone
based antibiotics. He was eventually stable for discharge
on POD # 94. He was discharged to a rehabilitation facility
and recently discharged to home.
Implantation technique
In order to avoid the scar tissue related to the prior car-
diac surgery, a deliberate procedure was planned to
establish an inflow site, outflow site, and LVAD pocket.
As such, a mini-upper-sternotomy, a limited left thora-
cotomy, and a partial midline upper abdominal pre-peri-
toneal laparotomy was instituted (Figures 1,2).
Cardiolpulmonary (CPB) bypass was established with an
aortic cannula and a femoral venous cannula. However,
CPB could have been established in other ways, includ-
ing femoral artery and vein, femoral vein and aorta,
femoral artery and right atrium (RA), or aorta and right
atrium. Our preference was to establish aorta and
femoral vein since we could identify enough aorta for
direct cannulation and allow for an outflow graft; addi-
tionally, femoral venous cannulation allowed us to avoid
extending the mini sternotomy in order to expose the
RA. In all three cases, three-dimensional CT Scanning
of the chest with accompanying CT angiography
(including the femoral vessels) was helpful in planning
the incisions and cannulation strategy. We could easily
determine where to extend (and limit) the upper ster-
notomy, where to locate the anterolateral thoracotomy
over the LV apex, and whether or not the femoral ves-
sels or aorta could be used for CPB. The surgical find-
ings in all three cases were noteworthy and could be
described independently: cannulation, inflow, outflow,
and LVAD pocket.
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Cannulation
Since it was our preference to establish CPB using the
femoral vein and aorta–understanding that alternatives
are perfectly acceptable–we performed a mini upper
sternotomy with a hockey-stick incision to the right lat-
eral side. The extent of the incision was based on the
CT scan and the goal was to expose the aorta up to its
root for cannulation and outflow graft attachment.
Figure 1 Preoperative Chest CT Scan.
Figure 2 Preoperative plan with HM-II™ Model.
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Femoral venous cannulation was performed in a stan-
dard fashion with a guidewire passed into the right
heart and confirmed in position by TEE–a suitable size
percutaneous venous cannula (e.g. 21 Fr) was positioned
accordingly.
Inflow
Although absolute identification of the LV apex with the
limited exposure was a concern, we were confident that
we were in the correct area based on the preoperative
CT scan. Although we did not need to remove or delib-
erately divide a rib, we were prepared to do so if needed.
Transesophageal echocardiography (TEE) was essential
in confirming the inflow site. Once the thoracotomy
incision was made and the ribs spread apart to expose
the LV apex (Figure 3), we made a small ventriculotomy
and inserted a Foley catheter with a 30 cc balloon and
inflated it, watching the entire process with trans-eso-
phageal echocardiography (TEE). In the event that we
were in a suboptimal location, we were prepared to
close the ventriculotomy with a mattress-pledgetted
suture, much like that performed for LV apical vent clo-
sure. It should be noted that we were already cannulated
for CPB prior to any of these maneuvers.
Outflow
The outflow graft was directed toward the anterolateral
aspect of the aorta. The hockey-stick incision was help-
ful in exposing enough aorta to determine cannulation
and outflow graft location (Figure 4). However, in the
cases in which prior bypass grafts were present, we were
prepared to cannulate the femoral artery or right axillary
artery to provide more space on the ascending aorta. An
opening in the right pleura from the mini-sternotomy
and another pleurotomy over the right hemidiaphragm
permitted the outflow graft to curve from the LVAD
pocket site up to the distal anastamosis site.
LVAD Pocket
An upper pre-peritoneal incision was made and the
LVAD pocket created in the subrectus muscle plane.
Dissection laterally to both sides allowed for direct com-
munication to the inflow site on the patient’s left and
the outflow pathway in the hemithorax on the patient’s
right side. The connections were easily established and
no distortion or kinking of the LVAD was encountered
in the varied body profiles of the patients described.
Discussion
The use of LVADs for end-stage heart failure patients as
a Destination Therapy device is growing in popularity,
largely because transplantation numbers are stagnant
and medical therapy has done little to change the prog-
nosis of Class IV or Stage D patients who fail to
respond to optimal treatment. However, many of the
DT patients are older and sicker than their BTT coun-
terparts and often have had prior cardiac surgery and
significant co-morbidities. The risk of the LVAD
implantation, therefore, is increased and methods to
reduce the risk should be instituted. As such, preopera-
tive maneuvers–such as nutritional optimization,
Figure 3 Intraop Exposure of LV Apex.
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improvement in right heart parameters, correction of
hematologic abnormalities, and so forth–have translated
into less perioperative problems [5,6]. Postoperative man-
euvers have similarly resulted into better outcomes as a
more formal critical care approach to the complexities of
all the organ systems is addressed [7,8]. Intraoperatively,
any maneuver that can minimize trauma and avoid com-
plication–bleeding or otherwise–is worth exploring. Thus,
the alternative technique described above accomplishes
the goal of implanting the LVAD without exposing the
entire heart. A similar approach was described by Gregoric
et al as well as Anyanwu in which a right thoracotomy and
left subcostal incision were utilized [9,10]. Recently,
Schmitto et al described placement of an implantable cen-
trifugal pump using an upper hemisternotomy and antero-
lateral thoracotomy [11]. These authors found this
approach to be less invasive and less traumatic in terms of
potential for intraoperative catastrophes and postoperative
bleeding. We found our approach to provide similar
advantages and have now adopted our technique for all
implants, high risk and otherwise.
The favorable features of the alternative technique
described as well as those referenced are several. For
example, the LV apex in end-stage heart failure patients is
so laterally displaced that a true midline approach requires
an extensive lateral dissection for proper orientation of the
inflow cannula. On the contrary, the limited lateral thora-
cotomy is directly over the LV apex making the inflow
connection far easier. In addition, the traditional trans-
sternal approach requires extensive dissection through
scar tissue in redo cases, thereby putting into jeopardy
previously placed bypass grafts; the scar tissue dissection
alone can result in excessive bleeding even in the absence
of previous grafts. Furthermore, inadvertent entry into the
right ventricle or other cardiac chamber can be disastrous.
These aspects were of particular concern in the first case
described. We deliberately wanted to avoid the dense
adhesions of the CorCap™, which is an artificial material
that fixes firmly to the heart and surrounding tissues. The
hazards of reoperating on a patient with a previously
placed CorCap™ was well described by Schroder and col-
leagues during the cardiectomy of the recipient at the time
of transplantation [12].
In summary, we describe an alternative technique of
LVAD implantation in high risk DT patients that mini-
mizes the potential for intraoperative complications.
The cases themselves are illustrative of this point, how-
ever, the high risk nature of the procedure is still readily
apparent. Although we avoided potential intraoperative
problems, the “high-risk” nature of the case shifted
more toward the patient profile than the operative tech-
nique. This was poignantly presented by Vitale and
others in their manuscript entitled “A call for guidance
in the use of left ventricular assist devices in older
adults” [13]. In retrospect, perhaps the lesson of these
cases is to apply the technique to a less morbid popula-
tion where the benefit of the surgical modification may
be better appreciated.
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Figure 4 Intraoperative exposure of Aorta with Outflow Graft.
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